Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Solna – page 46

745 clinical trials in Solna, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Solna at a glance
745
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

745 trials in Solna

Open in trial search

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Colorectal cancer

Not recruiting

Study of organ preservation using chemoradiotherapy and transanal surgery compared to standard surgery in patients with early rectal cancer (STAR-TREC trial)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:The University Of Birmingham

EGFR gene mutation+1

Not recruiting

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Vestre Viken HF

Neoplasm malignant

Not recruiting

Study of Nivolumab and Entinostat for Children and Adolescents with High-Risk Refractory or Relapsed Malignant Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Entinostat
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Hormone-dependent prostate cancer

Not recruiting

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:LEO PHARMA A/S

Hormone-refractory prostate cancer

Not recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Novartis Pharma AG

Haemophilia B with anti factor IX+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Hypertriglyceridaemia

Not recruiting

Study on the Safety of A24110He for Patients with Type 2 Diabetes and High Triglycerides

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Lipigon Pharmaceuticals AB

Prophylaxis against transplant rejection

Not recruiting

Study on Siplizumab and Rabbit Anti-Thymocyte Globulin for Preventing Rejection in New Kidney Transplant Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Itb-Med AB

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Solna

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on advanced cancer treatments, including studies for prostate cancer, melanoma, breast cancer, and lung cancer. Research aims to evaluate new therapeutic approaches and combination treatments.

  • Metastatic Prostate Cancer Therapy
  • Stage III Melanoma Treatment
  • Advanced Breast Cancer Management
  • Early-Stage Lung Cancer Intervention

Studies evaluate innovative therapies and compare their effectiveness to standard treatments.

02 Metabolic and Endocrine Disorders

Research investigating treatments for metabolic conditions and hormonal disorders, including obesity, diabetes, and polycystic ovary syndrome.

  • Obesity Management Studies
  • PCOS Treatment Alternatives
  • Diabetes Response Mechanisms

Trials examine both conventional and alternative therapeutic approaches.

03 Respiratory and Immunological Studies

Investigations into respiratory conditions and immune system responses, focusing on asthma, nasal polyps, and pediatric respiratory disorders.

  • Asthma Treatment Innovation
  • Chronic Rhinosinusitis Management
  • Pediatric Wheezing Prevention

Research aims to develop more effective treatments and preventive strategies.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.